Literature DB >> 20069330

The relation of serum vascular endothelial growth factor level with disease duration and activity in patients with rheumatoid arthritis.

Levent Ozgonenel1, Esra Cetin, Sule Tutun, Pinar Tonbaklar, Hale Aral, Guvenc Guvenen.   

Abstract

Vascular endothelial growth factor (VEGF) is known to be involved in the pathogenesis of rheumatoid arthritis (RA). In order to elucidate the association between VEGF levels and RA disease activity, VEGF concentrations were measured in RA patients at different phases and severity levels. Thirty-eight healthy subjects and 40 patients with RA were prospectively included in the study. Subjects were further categorized into four subgroups (high, moderate, low, or remission) using the disease activity score-28 (DAS28) scoring system. VEGF levels were significantly higher in patients than controls (p < 0.001). VEGF levels differed significantly in controls, early and late-phase RA patients (p = 0.002). A significant difference was found between controls and patients with high RA disease activity scores (p < 0.0001). VEGF levels were not correlated with age (r = -0.016; p = 0.921) or sex (r = 0.209; p = 0.921). VEGF values were correlated with erythrocyte sedimentation rate (r = 0.445; p = 0.004), but was not correlated with serum rheumatoid factor levels (r = -0.130; p = 0.424) in the patient group. In conclusion, higher VEGF levels are associated with late phase and high disease activity in RA, independent of age and sex.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20069330     DOI: 10.1007/s10067-009-1343-4

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  26 in total

1.  Serum vascular endothelial growth factor in late rheumatoid arthritis.

Authors:  G R Pinheiro; C A Andrade; C R Gayer; M S Coelho; S M Freire; M A Scheinberg
Journal:  Clin Exp Rheumatol       Date:  2001 Nov-Dec       Impact factor: 4.473

2.  A study on vascular endothelial growth factor and endothelin-1 in patients with extra-articular involvement of rheumatoid arthritis.

Authors:  Anna Kuryliszyn-Moskal; Piotr Adrian Klimiuk; Stanisław Sierakowski; Mariusz Ciolkiewicz
Journal:  Clin Rheumatol       Date:  2005-10-25       Impact factor: 2.980

3.  A simplified disease activity index for rheumatoid arthritis for use in clinical practice.

Authors:  J S Smolen; F C Breedveld; M H Schiff; J R Kalden; P Emery; G Eberl; P L van Riel; P Tugwell
Journal:  Rheumatology (Oxford)       Date:  2003-02       Impact factor: 7.580

Review 4.  Serum vascular markers and vascular imaging in assessment of rheumatoid arthritis disease activity and response to therapy.

Authors:  P C Taylor
Journal:  Rheumatology (Oxford)       Date:  2005-01-11       Impact factor: 7.580

5.  Soluble adhesion molecules (ICAM-1, VCAM-1, and E-selectin) and vascular endothelial growth factor (VEGF) in patients with distinct variants of rheumatoid synovitis.

Authors:  P A Klimiuk; S Sierakowski; R Latosiewicz; J P Cylwik; B Cylwik; J Skowronski; J Chwiecko
Journal:  Ann Rheum Dis       Date:  2002-09       Impact factor: 19.103

Review 6.  Angiogenesis--a new target for future therapy.

Authors:  Nilesh M Pandya; Naranjan S Dhalla; Dev D Santani
Journal:  Vascul Pharmacol       Date:  2006-03-20       Impact factor: 5.773

7.  Therapeutic effect of anti-vascular endothelial growth factor receptor I antibody in the established collagen-induced arthritis mouse model.

Authors:  Sang Tae Choi; Ji Hye Kim; Jae-Yeon Seok; Yong-Beom Park; Soo-Kon Lee
Journal:  Clin Rheumatol       Date:  2008-12-20       Impact factor: 2.980

8.  Angiogenesis markers (VEGF, soluble receptor of VEGF and angiopoietin-1) in very early arthritis and their association with inflammation and joint destruction.

Authors:  Gaëlle Clavel; Natacha Bessis; Delphine Lemeiter; Patrice Fardellone; Othmane Mejjad; Jean-Francois Ménard; Sophie Pouplin; Patrick Boumier; Olivier Vittecoq; Xavier Le Loët; Marie-Christophe Boissier
Journal:  Clin Immunol       Date:  2007-06-08       Impact factor: 3.969

9.  Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor alpha and interleukin-1 in rheumatoid arthritis.

Authors:  E M Paleolog; S Young; A C Stark; R V McCloskey; M Feldmann; R N Maini
Journal:  Arthritis Rheum       Date:  1998-07

10.  Vascular permeability factor/endothelial growth factor (VPF/VEGF): accumulation and expression in human synovial fluids and rheumatoid synovial tissue.

Authors:  R A Fava; N J Olsen; G Spencer-Green; K T Yeo; T K Yeo; B Berse; R W Jackman; D R Senger; H F Dvorak; L F Brown
Journal:  J Exp Med       Date:  1994-07-01       Impact factor: 14.307

View more
  8 in total

1.  Angiogenic growth factors in rheumatoid arthritis.

Authors:  Malte Schroeder; Lennart Viezens; Ina Fuhrhop; Wolfgang Rüther; Christian Schaefer; Britta Schwarzloh; Petra Algenstaedt; Bernd Fink; Nils Hansen-Algenstaedt
Journal:  Rheumatol Int       Date:  2011-11-09       Impact factor: 2.631

Review 2.  Systematic Review: Targeted Molecular Imaging of Angiogenesis and Its Mediators in Rheumatoid Arthritis.

Authors:  Fatemeh Khodadust; Aiarpi Ezdoglian; Maarten M Steinz; Judy R van Beijnum; Gerben J C Zwezerijnen; Gerrit Jansen; Sander W Tas; Conny J van der Laken
Journal:  Int J Mol Sci       Date:  2022-06-25       Impact factor: 6.208

3.  Performance of a multi-biomarker score measuring rheumatoid arthritis disease activity in the CAMERA tight control study.

Authors:  Marije F Bakker; Guy Cavet; Johannes Wg Jacobs; Johannes W J Bijlsma; Douglas J Haney; Yijing Shen; Lyndal K Hesterberg; Dustin R Smith; Michael Centola; Joel A G van Roon; Floris P J G Lafeber; Paco M J Welsing
Journal:  Ann Rheum Dis       Date:  2012-05-17       Impact factor: 19.103

4.  Circulating cytokine profiles and their relationships with autoantibodies, acute phase reactants, and disease activity in patients with rheumatoid arthritis.

Authors:  Pieter W A Meyer; Bridget Hodkinson; Mahmood Ally; Eustasius Musenge; Ahmed A Wadee; Heidi Fickl; Mohammed Tikly; Ronald Anderson
Journal:  Mediators Inflamm       Date:  2011-03-02       Impact factor: 4.711

5.  Serum Markers in Rheumatoid Arthritis: A Longitudinal Study of Patients Undergoing Infliximab Treatment.

Authors:  Oddgeir Selaas; Hilde H Nordal; Anne-Kristine Halse; Johan G Brun; Roland Jonsson; Karl A Brokstad
Journal:  Int J Rheumatol       Date:  2015-12-16

6.  The Relationship Between Serum Angiogenic Factor Levels and Disease Activity in Rheumatoid Arthritis.

Authors:  Zahide Aslanalp; Canan Tikiz; Aslıhan Ulusoy; Şebnem Orguc; Aysun Bİlgİ Yedekcİ; Cevval Ulman
Journal:  Arch Rheumatol       Date:  2020-01-08       Impact factor: 1.472

7.  Relationship between VEGF Gene Polymorphisms and Serum VEGF Protein Levels in Patients with Rheumatoid Arthritis.

Authors:  Agnieszka Paradowska-Gorycka; Andrzej Pawlik; Katarzyna Romanowska-Prochnicka; Ewa Haladyj; Damian Malinowski; Barbara Stypinska; Malgorzata Manczak; Marzena Olesinska
Journal:  PLoS One       Date:  2016-08-11       Impact factor: 3.240

8.  VEGF Gene Polymorphisms Affect Serum Protein Levels and Alter Disease Activity and Synovial Lesions in Rheumatoid Arthritis.

Authors:  Jin-Ping Yi; Yu-Zhang Wu; Nan Yu; Zhi-Wu Yu; Fu-Yuan Xie; Quan Yuan
Journal:  Med Sci Monit       Date:  2016-01-30
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.